BMY|Analyst Targets
BMY|Company Info
BMY|Insider Trading
BMY|Fundamentals
BMY|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.39 | - | - |
| Q2'26 | $1.60 | $2.04 | +27.4% |
| Q1'26 | $1.42 | $1.58 | +11.1% |
| Q4'25 | $1.13 | $1.26 | +11.9% |
| Q3'25 | $1.52 | $1.63 | +7.6% |
| Q2'25 | $1.10 | $1.46 | +32.6% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $12.7B | - | - |
| Q2'26 | $11.9B | $13.0B | +9.4% |
| Q1'26 | $10.9B | $11.5B | +5.2% |
| Q4'25 | $12.4B | $12.5B | +0.8% |
| Q3'25 | - | $12.2B | - |
| Q2'25 | - | $12.3B | - |
BMY|Monthly Returns
Market Data
BMY Stock Snapshot
- Market cap
- 116.02B
- P/E ratio
- 12.5
- Day range
- $56.58 – $58.66
- News sentiment
- 57/100 · Neutral
- Analyst target
- $65.83 (+12.2%)
- Consensus
- Hold · 36 analysts
Price is in the middle of its 52-week range, and the momentum read backs that positioning up. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.
Reverse DCF
What growth is priced into BMY?
At today's price, Bristol-Myers Squibb Company needs to grow free cash flow about -14.1% a year for the next 10 years to justify its valuation at a 6.58% cost of capital. Over its actual history it has compounded free cash flow at 10.8% a year, so the market is asking for 24.9 percentage points below its own delivered rate. On that basis BMY looks priced below what its own growth record supports.
- Implied FCF growth
- -14.1%
- Historical FCF CAGR
- 10.8%
- Growth gap
- -24.9 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 6.58%
- Beta
- 0.53
Behaviour On Record
What BMY's own history says about today's numbers
- Realized volatility (21d)
- 21.8% 51st pct
- Below its peak
- -29.2%
- vs 200-day average
- -3.7%
- Up days (1y)
- 50%
Bristol-Myers Squibb Company is currently running 21.8% annualised volatility over the last 21 sessions. Measured against BMY's own 13 years of daily returns rather than a market-wide average, that is the 51st percentile — close to its own typical level, against a typical reading of 21.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
BMY is trading -29.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -24.7%, and the deepest was -36.3% in 2016. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -3.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 36th percentile — close to the gap it normally carries. Over the past year BMY closed higher on 50% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 14 years of records, BMY finished the month higher 6 of 14 times, with a median return of -2.0% and an average of +0.6%. Its strongest month historically has been February at +3.4% on average, its weakest April at -2.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: BMY has opened more than 2% away from the prior close in 44 of 3,268 sessions (1.3% of the time), with the largest gaps running +6.8% and -5.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, BMY moved an average of 2.4% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.7% and a largest of +3.8%.
All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against BMY's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of BMY's sector?
Bristol-Myers Squibb Company sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 91
Analyst Rating Changes
Are analysts turning bullish or bearish on BMY?
Wells Fargo most recently reiterated its rating on Bristol-Myers Squibb Company to Equal-Weight on Oct 13, 2026 with a price target of $60 (from $65). Over the last 90 days, coverage has run 1 upgrade against 1 downgrade, a net mixed lean.
- Latest action
- Wells Fargo — Equal-Weight
- 90-day upgrades
- 1
- 90-day downgrades
- 1
- Net rating momentum
- 0
Peers & ETF holders
BMY peers & ETF holders
Drug Manufacturers - GeneralMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 198,727,768 | 9.82% | $10.72B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 180,384,994 | 8.92% | $10.39B | 2026-08-07 |
| JPMorgan Chase & Co | ▼ Sell | 71,713,442 | 3.54% | $4.20B | 2026-08-12 |
| Geode Capital Management, LLC | ▲ Buy | 56,443,077 | 2.79% | $3.24B | 2026-08-12 |
| Norges Bank | ▲ Buy | 36,866,658 | 1.82% | $2.12B | 2026-08-12 |
| Bank of America Corp | ▲ Buy | 34,045,352 | 1.68% | $1.96B | 2026-08-14 |
| Morgan Stanley | ▼ Sell | 29,009,025 | 1.43% | $1.67B | 2026-08-13 |
| AQR Capital Management LLC | ▼ Sell | 27,357,486 | 1.35% | $1.58B | 2026-08-14 |
| Northern Trust Corp | ▲ Buy | 24,918,384 | 1.23% | $1.44B | 2026-08-13 |
| Goldman Sachs Group Inc | ▲ Buy | 17,016,799 | 0.84% | $980.51M | 2026-08-14 |
| FMR LLC (Fidelity) | ▲ Buy | 16,293,303 | 0.81% | $938.82M | 2026-08-13 |
| Invesco Ltd. | ▲ Buy | 16,033,480 | 0.79% | $923.85M | 2026-08-14 |
| Two Sigma Investments, LP | ▼ Sell | 10,085,383 | 0.50% | $581.12M | 2026-08-14 |
| Wells Fargo & Company | ▲ Buy | 6,321,643 | 0.31% | $364.25M | 2026-08-14 |
| AllianceBernstein L.P. | ▼ Sell | 4,757,720 | 0.24% | $288.56M | 2026-08-14 |
| Man Group plc | ▼ Sell | 4,682,000 | 0.23% | $269.78M | 2026-08-14 |
| Wellington Management Group LLP | ▼ Sell | 3,914,086 | 0.19% | $225.53M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 3,370,113 | 0.17% | $194.19M | 2026-08-03 |
| Capital World Investors | ▲ Buy | 2,244,242 | 0.11% | $129.31M | 2026-08-12 |
| Prudential Financial Inc | ▲ Buy | 1,794,030 | 0.09% | $103.37M | 2026-08-12 |
| Adage Capital Partners GP, L.L.C. | ▲ Buy | 1,716,000 | 0.08% | $98.88M | 2026-08-14 |
| Citadel Advisors LLC | ▲ Buy | 1,572,329 | 0.08% | $90.60M | 2026-09-02 |
| Neuberger Berman Group LLC | ▲ Buy | 972,843 | 0.05% | $56.06M | 2026-08-13 |
| Janus Henderson Group plc | ▼ Sell | 912,926 | 0.05% | $55.37M | 2026-05-18 |
| Gotham Asset Management, LLC | ▲ Buy | 892,969 | 0.04% | $51.45M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Mike Kelly | House | PA16 | ▼ Sell | $15K - $50K | 2026-05-07 | 2026-06-11 |
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-12-19 | 2026-01-12 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-12-18 | 2026-01-15 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-11-13 | 2025-12-11 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-11-12 | 2025-12-15 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-08-14 | 2025-09-11 |
| Virginia Foxx | House | NC05 | ▼ Sell | $1K - $15K | 2025-06-24 | 2025-07-03 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-05-12 | 2025-06-22 |
| Julia Letlow | House | LA05 | ▼ Sell | $1K - $15K | 2025-04-28 | 2026-01-13 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2025-04-15 | 2026-08-05 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-04-01 | 2025-05-14 |
| Greg Landsman | House | OH01 | ▼ Sell | $1K - $15K | 2025-03-27 | 2025-04-08 |
| Julie Johnson | House | TX32 | ▲ Buy | $1K - $15K | 2025-01-15 | 2025-02-12 |
| Valerie Hoyle | House | OR04 | ▲ Buy | $1K - $15K | 2024-10-29 | 2025-09-12 |
| Julia Letlow | House | LA05 | ▲ Buy | $1K - $15K | 2024-10-23 | 2026-01-13 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2024-04-03 | 2024-05-15 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2024-04-03 | 2024-05-15 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2024-01-03 | 2024-02-14 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2023-11-16 | 2023-12-15 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2023-10-17 | 2023-11-16 |
| Dan Sullivan | Senate | AK | ▼ Sell | $1K - $15K | 2023-08-22 | 2023-09-22 |
| Shelley Moore Capito | Senate | WV | ▼ Sell | $1K - $15K | 2023-05-10 | 2023-06-14 |
| Dan Sullivan | Senate | AK | ▼ Sell | $1K - $15K | 2023-01-10 | 2023-02-13 |
| Shelley Moore Capito | Senate | WV | ▼ Sell | $1K - $15K | 2022-06-17 | 2022-07-15 |